Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 10, 2005, Pages 688-690

  Harbarth, S ^a   Garbino, J ^a   Pugin, J ^a   Romand, J A ^a   Pittet, D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATALITY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; SURVIVAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PNEUMOCOCCAL INFECTIONS; SEPSIS; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 27944446850     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0018-6     Document Type: Article

References (9)

1. Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837-1842
2. Martinez JA, Horcajada JP, Almela M, et al (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389-395
3. Baddour LM, Yu VL, Klugman KP, et al (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440-444
4. File Jr TM, Mandell LA (2003) What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis 36:396-398
5. Abraham E, Glauser MP, Butler T, et al (1997) P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 277:1531-1538
6. Abraham E, Laterre PF, Garbino J, et al (2001) Lenercept in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled trial. Crit Care Med 29:503-510
7. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115:529-535
8. Cohen J, Abraham E (1999) Microbiologic findings and correlations with tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 180:116-121
9. Perry TR, Schentag JJ (2001) Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet 40:685-694